Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer
NCT04340141Phase 3Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Oct 2020
- Primary completion
- Dec 2028
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
A Phase 3 trial of fluorouracil, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, folinic acid, oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by Cancer and Leukemia Group B. Started Oct 2020; status: active, not recruiting.
02
Drugs
fluorouracilirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfolinic acidoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04340141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04340141.